Home › Kidney Failure › NCT05931276
CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes (BRAVO)
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * On hemodialysis * Received one of the following beta blockers through the VA pharmacy: metoprolol (succinate or tartrate), atenolol, labetalol, carvedilol, bisoprolol Exclusion Criteria: * Impaired decision-making capacity * Patients not receiving carvedilol who have a history of asthma * known hypersensitivity to any component of either drug * Provider unwilling to sign a new medication order for a randomized patient * No surrogate consent will be allowed
About the study
The investigators aim to determine, using a point-of-care randomized controlled trial design, if hemodialysis patients, who are randomized to metoprolol succinate (a dialyzable, beta-1 selective beta blocker), have an improved cardiovascular outcome compared to those randomized to carvedilol (a non-dialyzable, non-selective beta blocker with alpha-1 antagonist properties). The investigators will also examine intervention practices to identify components that best support engagement and sustainability.
What is being tested
- Metoprolol Succinate (drug)
- Carvedilol (drug)
Sponsor: VA Office of Research and Development · Participants: 2,540 · Started: May 22, 2024
Contact the study team
- Jade Fiotto · Phone: (617) 232-9500
Official record on ClinicalTrials.gov — NCT05931276
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.